Journal article
In vivo white matter microstructure in adolescents with early-onset psychosis: a multi-site mega-analysis
C Barth, S Kelly, S Nerland, N Jahanshad, C Alloza, S Ambrogi, OA Andreassen, D Andreou, C Arango, I Baeza, N Banaj, CE Bearden, M Berk, H Bohman, J Castro-Fornieles, Y Chye, B Crespo-Facorro, E de la Serna, CM Díaz-Caneja, TP Gurholt Show all
Molecular Psychiatry | Published : 2023
Abstract
Emerging evidence suggests brain white matter alterations in adolescents with early-onset psychosis (EOP; age of onset <18 years). However, as neuroimaging methods vary and sample sizes are modest, results remain inconclusive. Using harmonized data processing protocols and a mega-analytic approach, we compared white matter microstructure in EOP and healthy controls using diffusion tensor imaging (DTI). Our sample included 321 adolescents with EOP (median age = 16.6 years, interquartile range (IQR) = 2.14, 46.4% females) and 265 adolescent healthy controls (median age = 16.2 years, IQR = 2.43, 57.7% females) pooled from nine sites. All sites extracted mean fractional anisotropy (FA), mean dif..
View full abstractRelated Projects (2)
Grants
Awarded by Instituto de Investigación Sanitaria Gregorio Marañón
Funding Acknowledgements
ENIGMA Core: U.S. National Institutes of Health grants, R01 EB015611, U54 EB020403, R01 MH116147, R01 MH117601, R01 MH121246, S10 OD023696. YTOP: The Research Council of Norway (223273, 2137000, 250358, 288083); South-Eastern Norway Regional Health Authority (2017112, 2022080); KG Jebsen Stiftelsen (SKGJ-MED-008). MADRID: Celso Arango has received funding from CIBERSAM: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, co-financed by ERDF Funds from the European Commission, "A way of making Europe"; CIBERSAM; Instituto de Investigacion Sanitaria Gregorio Maranon; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2, Youth Employment Operational Program and Youth Employment Initiative); European Social Fund and EU Structural Funds; EU Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909, FP7-HEALTH-2009-2.2.1-3-242114, FP7-HEALTH-2013-2.2.1-2-602478, and FP7HEALTH-2013-2.2.1-2-603196; EU H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundacion Familia Alonso, Fundacion Alicia Koplowitz and Fundacion Mutua Madrilena. Covadonga M. Diaz-Cenaj has received grant support from Instituto de Salud Carlos III (PI17/00481, PI20/00721, JR19/00024). FEMS: This project was supported by an unrestricted grant from AstraZeneca. Michael Berk is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1059660 and APP1156072). SCAPS: The Swedish Research Council (521-2014-3487, 2017-00949); FORMAS (2592012-31). OXFORD: MRC G0500092. PAFIP: This study was supported by grants from Carlos III Health Institute (IPI17/00402, PI17/01056, PI14/00639 and PI14/00918) cofunded by The European Union through FEDER funds and Fundacion Instituto de Investigacion Marques de Valdecilla (NCT0235832 and NCT02534363). No pharmaceutical company has financially supported the study. BARCELONA: Inmaculada Baeza has received research funds from the Spanish Ministry of Health, Instituto de Salud Carlos II, supported by ERDF Funds from the European Comission (PI18/0242 and PI21/0391), "Otra manera de hacer Europa", and Fundacion Alcia Koplowitz. Elena de la Serna has received grant support from Instituto de Salud Carlos III (PI20/00654). Gisela Sugranyes has received research funds from Instituto de Salud Carlos III (PI1800976 and PI2100330), the Alicia Koplowitz Foundation (AKOPLOWITZ20_004), Ajut a la Recerca Pons Bartran (FCRB_PB1_2018) and a Brain and Behaviour Research Foundation NARSAD 2017 Young Investigator Grant (26731). UCLA: NIMH grants U01MH081902, P50MH066286. We thank the research team and participants at each contributing site for the opportunity to conduct this research.